parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.05 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including oligodendrocyte progenitor cells; strongest in pituitary stem cells	0.75
chemistry Open Targets	hard to drug	0.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	1 Parkinson's papers of 44	0.91
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 5304

receipt 5313: FIGN in dopamine neurons, braak

power: full sample +0.16 (p 0.526, n 18), 95% CI -0.33 to +0.58. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.11 (p 0.664, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.17 (p 0.493, n 18). could be the mix.
skeptic: leave-one-out range +0.06 to +0.32, sign flips 0; without severely affected donors +0.16 (p 0.526, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for FIGN in dopamine neurons.

case closed: nothing better to follow up.

receipt 5312: FIGN in oligodendrocytes, braak

power: full sample -0.12 (p 0.640, n 18), 95% CI -0.55 to +0.37. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.09 (p 0.715, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.08 (p 0.748, n 18). could be the mix.
skeptic: leave-one-out range -0.23 to +0.01, sign flips 1; without severely affected donors -0.12 (p 0.640, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for FIGN in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts